These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 23231975)

  • 1. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
    Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
    J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration.
    Takebe N; Ahmed MM; Vikram B; Bernhard EJ; Zwiebel J; Norman Coleman C; Kunos CA
    Semin Radiat Oncol; 2016 Oct; 26(4):271-80. PubMed ID: 27619249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy.
    Lin SH; George TJ; Ben-Josef E; Bradley J; Choe KS; Edelman MJ; Guha C; Krishnan S; Lawrence TS; Le QT; Lu B; Mehta M; Peereboom D; Sarkaria J; Seong J; Wang D; Welliver MX; Coleman CN; Vikram B; Yoo S; Chung CH; ;
    J Natl Cancer Inst; 2013 May; 105(10):686-93. PubMed ID: 23503600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principles of chemoradiation: theoretical and practical considerations.
    Herscher LL; Cook JA; Pacelli R; Pass HI; Russo A; Mitchell JB
    Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):11-22. PubMed ID: 10550823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targets in radiotherapy.
    Brown JM
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):319-26. PubMed ID: 11173124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose escalation methods in phase I cancer clinical trials.
    Le Tourneau C; Lee JJ; Siu LL
    J Natl Cancer Inst; 2009 May; 101(10):708-20. PubMed ID: 19436029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New concepts for phase I trials: evaluating new drugs combined with radiation therapy.
    Deutsch E; Soria JC; Armand JP
    Nat Clin Pract Oncol; 2005 Sep; 2(9):456-65. PubMed ID: 16264990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxic radiosensitizers and hypoxic cytotoxins in radiation oncology.
    Weinmann M; Welz S; Bamberg M
    Curr Med Chem Anticancer Agents; 2003 Sep; 3(5):364-74. PubMed ID: 12871083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ; Moini M; Giuliano J; Westra WH
    Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive design may hasten clinical trials.
    Schmidt C
    J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors.
    Shulman LN; Buswell L; Riese N; Doherty N; Loeffler JS; von Roemeling RW; Coleman CN
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):349-53. PubMed ID: 10760430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.
    Wages NA; Tait C
    J Biopharm Stat; 2015; 25(5):903-20. PubMed ID: 24904956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents.
    Hoering A; Mitchell A; LeBlanc M; Crowley J
    Clin Trials; 2013; 10(3):422-9. PubMed ID: 23529697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical radiosensitizers for use in radiotherapy.
    Wardman P
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):397-417. PubMed ID: 17478086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial designs for targeted agents.
    Ma BB; Britten CD; Siu LL
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1287-305. PubMed ID: 12512393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunities and challenges in the development of experimental drug combinations for cancer.
    Humphrey RW; Brockway-Lunardi LM; Bonk DT; Dohoney KM; Doroshow JH; Meech SJ; Ratain MJ; Topalian SL; Pardoll DM
    J Natl Cancer Inst; 2011 Aug; 103(16):1222-6. PubMed ID: 21765011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovation in oncology clinical trial design.
    Verweij J; Hendriks HR; Zwierzina H;
    Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A combination phase I/II study--dose escalation plan].
    Yamamoto N
    Gan To Kagaku Ryoho; 2000 Dec; 27(14):2267-74. PubMed ID: 11142175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.